- Stocks
- Healthcare
- NASDAQ: EDIT

Price (delayed)

$49.76

Market cap

$3.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$2.85B

Editas Medicine's gross profit has soared by 181% from the previous quarter

The revenue has soared by 181% since the previous quarter

The debt has soared by 51% YoY but it has contracted by 7% from the previous quarter

What are the main financial stats of EDIT

Market
Valuations
Earnings

Shares outstanding

62.33M

Market cap

$3.1B

Enterprise value

$2.85B

Price to earnings (P/E)

N/A

Price to book (P/B)

7.02

Price to sales (P/S)

33.76

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

31.1

Revenue

$91.6M

EBIT

-$98.56M

EBITDA

-$95M

Free cash flow

-$106.11M

Per share
Balance sheet
Liquidity

EPS

-$1.72

Free cash flow per share

-$1.71

Book value per share

$7.08

Revenue per share

$1.47

TBVPS

$9.61

Total assets

$597.16M

Total liabilities

$156.01M

Debt

$26.71M

Equity

$441.15M

Working capital

$452.01M

Debt to equity

0.06

Current ratio

9.25

Quick ratio

9.06

Net debt/EBITDA

2.66

Margins
Efficiency
Dividend

EBITDA margin

-103.7%

Gross margin

100%

Net margin

-99.6%

Operating margin

-118.3%

Return on assets

-16.4%

Return on equity

-26.7%

Return on invested capital

-46.3%

Return on capital employed

-18.2%

Return on sales

-107.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Editas Medicine stock price performed over time

Intraday

1.26%

1 week

-11.94%

1 month

-24.33%

1 year

110.05%

YTD

-29.03%

QTD

-29.03%

How have Editas Medicine's revenue and profit performed over time

Revenue

$91.6M

Gross profit

$91.6M

Operating income

-$108.39M

Net income

-$91.25M

Gross margin

100%

Net margin

-99.6%

Editas Medicine's gross profit has soared by 181% from the previous quarter

The revenue has soared by 181% since the previous quarter

The net margin has soared by 88% YoY and by 75% from the previous quarter

EDIT's operating margin has surged by 87% year-on-year and by 75% since the previous quarter

What is Editas Medicine's growth rate over time

What is Editas Medicine stock price valuation

P/E

N/A

P/B

7.02

P/S

33.76

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

31.1

EDIT's EPS is up by 31% since the previous quarter and by 30% year-on-year

EDIT's equity has soared by 110% year-on-year and by 3.4% since the previous quarter

EDIT's P/B is 53% above its last 4 quarters average of 4.6 and 35% above its 5-year quarterly average of 5.2

The revenue has soared by 181% since the previous quarter

The P/S is 62% less than the 5-year quarterly average of 88.5 and 27% less than the last 4 quarters average of 46.5

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 88% year-on-year and by 75% since the previous quarter

The ROE has soared by 53% YoY and by 43% from the previous quarter

Editas Medicine's ROA has increased by 48% YoY and by 38% from the previous quarter

EDIT's return on invested capital is up by 35% since the previous quarter and by 27% year-on-year

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

How did Editas Medicine financials performed over time

The current ratio has soared by 82% YoY and by 3.4% from the previous quarter

Editas Medicine's quick ratio has surged by 82% YoY and by 2.8% QoQ

The debt is 94% less than the equity

EDIT's equity has soared by 110% year-on-year and by 3.4% since the previous quarter

The debt has soared by 51% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.